Medanta | Investor Relation

Annual General Meeting

Financial year 2022-23

AGM 2023_Trancsript

AGM Notice

AGM Proceedings

Post Dispatch Advertisement

Pre Dispatch Advertisement

Voting Results

Shareholders` information

No Data Found!

Shareholders FAQ

No Data Found!

IPO Documents

B.1_CTC of MOA & AOA

B.2_COI_13.08.2004

B.3_Fresh COI dated 11.08.2021

B.4_BR_Authorising Offer_17.09.2021

B.5_Shareholder Resolution_Authorising Offer_21.09.2021

B.6_BR Approving DRHP_29.09.2021

B.7_BR Approving Addendum to DRHP

B.8_BR and Shareholders Approval for Modification in OFS

B.9_BR_RHP Approval_22.10.2022

B.10_Consent Letter of Investor Selling Shareholder_11.10.2021

B.11_Share Purchase Agreement_13.05.2017

B.12_Scheme of amalgamation and merger of NTAHS with Co

B.13_SHA _29.10.2013

B.14_SHA _12.01.2015

b.15_RJ Corp_ Investment Agreeement_Suppl Agreement and Undertaking

B.15_Undertaking_05.10.2015 RJ Corp

B.16_Agreement dated 13.05.2017_ Dr. NT and SS

B.17_ Waiver Amendment and Termination Agreement_14 09 2021 and WATA Extn Letter June 30 2022

B.18_ Agreement_04.01.2022_Conversion of CCPS

B.19_Trademark Licence Agreement_25.11.2013

b.20_Resolutions for appoinment of Dr.NT as CMD

B.21_Resolutions for appoinmnet of Dr.NT as Chaiman-Heart Institute and CCS

B.22_ BR dated July 25, 2022 _Re-appoinment of Dr.NT as CMD and Chaiman-, Heart Institure and CCS

B.23_Annual Report 19-20

B.24_CA Examniation Report_02.09.22

B.25_Special tax Benefit Report_14.10.2022

B.26_Assessment of Health Delivery Market_26.09.2022_CRSIL

B.27_Consent for Assessment of Health Delivery Market_26.09.2022_CRSIL

B.28_Engagement Letter of CRISIl_15.09.22

B.29_ Consents

B.30_Consent of CA to Include their name in RHP as Expert with respect to Examnination Report _02.09.2022

B.31_Consent of RM Marwah CA to Include their name in RHP as Expert

B.32_Triparty Agreement btw Co NSDl & Registrar_09.04.2021

B.33_Triparty Agreement btw Co CDSl & Registrar_09.09.2021

B.34_DD Certificate_29.09.2021

B.35_In Principle Approval_21.10.21 and 22.10.21

B.36_Final Observation Letter_21.12.21

GHL Final MOA AOA 28 January, 2023

Investor Contact & feedback Form

Registered Office:

Global Health Limited
CIN: L85110DL2004PLC128319
Medanta-Mediclinic E-18,
Defence Colony
New Delhi-110024
Ph No.011- 44114411

Corporate Office:

Medanta – The Medicity,
Sector-38, Gurugram,
122001, Haryana
Phno: 124-483-4060

For Investor Grievances

Mr. Rahul Ranjan, Compliance Officer
Medanta – The Medicity,
Sector-38, Gurugram,122001, Haryana
Tel: 124 483 4060;
Email: : compliance@medanta.org

Registrar & Share Transfer Agent

KFIN Technologies Limited
Selenium, Tower-B
Plot 31 and 32, Financial District
Nanakramguda, Serilingampally
Hyderabad, Rangareddi 500 032
Telangana, India

Toll-Free/ Phone Number : 1800 309 4001

WhatsApp Number : (91) 910 009 4099

KFINTECH Corporate Website: https://www.kfintech.com

RTA Website : https://ris.kfintech.com

Investor Support Centre (DIY Link) https : //ris.kfintech.com/clientservices/isc

SEBI Registration No. : INR000000221

Online Dispute Resolution Login link: https://smartodr.in/intermediary/login

Contact Details of Key Managerial Personnel Under Regulation 30(5) of SEBI LODR, 2015

S. No

Name & Designation

Email address

Contact Number

Dr. Naresh Trehan,

Chairman & Managing Director

Naresh.Trehan@Medanta.org

Tel: +91 124 483 4060

Mr. Pankaj Sahni,

Group CEO & Director

Pankaj.Sahni@Medanta.org

Material Contracts For The Offer